急性心力衰竭藥物治療新進展-文庫吧資料
2024-10-19 17:56本頁面
【正文】 HF研究： 2020年， 《 JAMA》 雜志上也發(fā)表 《 Shortterm intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial》 ，與安慰劑相比，米力農(nóng)不良反應(yīng)與死亡發(fā)生率高。43:18726. 米力農(nóng)與 β 受體阻滯劑聯(lián)合治療 （ Meta分析） CONCLUSIONS: Data are insufficient to make firm conclusions on the clinical benefit of bination therapy with a bblocker and milrinone in patients with advanced HF, although it appears that this regimen is well tolerated and may allow weaning of inotropic support. Ann Pharmaco ther 2020。2(4):3204 (回顧性研究 ) 對比米力農(nóng)與多巴酚丁胺 —— 心衰患者預(yù)后 Circ Heart Fail. 2020 Jul。 死亡率 177。 靜脈給藥 5～ 15分鐘起生效， T1/2為 2～ 3小時。 其血管擴張作用可能是直接作用于小動脈所致，從而可降低心臟前、后負荷，降低左心室充盈壓，改善左室功能，增加心臟指數(shù)，但對平均動脈壓和心率無明顯影響。耐受性較好。兼有正性肌力作用和血管擴張作用。 臨床上應(yīng)用的傳統(tǒng)正性肌力藥物，如 β 受體激動劑和磷酸二酯酶抑制劑等。365:3243. ASCENDHF研究結(jié)論 N Engl J Med 2020。365:3243. ASCENDHF研究 N Engl J Med 2020。 JACC,2020， 53（ 15）， E190. ASCENDHF研究 N Engl J Med 2020。 they have been approved for use in the management of acute HF. In this setting, nesiritide has been shown to improve symptoms of acute HF, but the effect on morbidity and mortality has not been clear from available clinical are currently under investigation as adjunctive therapy。 NESIRITIDE Intavenous nesiritide, a rebinant form of human Btype natriuretic peptide, is a venous and arterial vasodilator with a bined modest diuretic and natriuretic effect. Intravenous nesiritide may be initiated with or without a bolus infusion. Noninvasive BP measurements are usually adequate. Combination with other . vasodilators is not remended. Nesiritide is not available in most European countries.
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1